{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:56:02Z","timestamp":1792119362668,"version":"4.4.0"},"reference-count":182,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32070732"],"award-info":[{"award-number":["32070732"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503908"],"award-info":[{"award-number":["82503908"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31970753"],"award-info":[{"award-number":["31970753"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["21ZR1477400"],"award-info":[{"award-number":["21ZR1477400"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Talent Development Foundation of Shanghai","award":["2021080"],"award-info":[{"award-number":["2021080"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cholangiocarcinoma (CCA) is a biologically diverse and highly aggressive cancer that arises from the biliary epithelium. It is typically divided into intrahepatic, perihilar, and distal types, each with distinct clinical behavior, genetic alterations, and therapeutic responses. Worldwide, the global incidence of CCA has risen steadily, accounting for nearly 15% of liver cancers and \u223c3% of all gastrointestinal malignancies. CCA often presents at an advanced stage due to its silent onset and shows poor responsiveness to conventional chemotherapy, resulting in high mortality, accounting for \u223c2% of cancer-related deaths worldwide. Risk factors include parasitic infections like liver flukes and chronic biliary diseases such as cholelithiasis and primary sclerosing cholangitis, although most cases have unknown origins. While early-stage patients may benefit from surgical resection or liver transplantation, these options are often not viable in advanced disease due to high relapse rates. In cases of unresectable or metastatic CCA, treatment remains difficult due to resistance and a lack of effective targeted therapies. This review systematically integrates the genomic, epigenetic, and signaling network mechanisms underlying CCA with their translational implications, providing a critical synthesis of the rapidly evolving field of targeted therapies, including recently approved Food and Drug Administration treatments and emerging novel agents. We specifically emphasize the key mechanisms of therapeutic resistance and corresponding strategies to overcome them, present an updated evaluation of vulnerabilities across distinct molecular subgroups, and explore the major challenges and future trajectories for advancing biomarker-driven precision medicine in CCA, thereby offering a forward-looking and clinically relevant perspective.<\/jats:p>","DOI":"10.1093\/pcmedi\/pbaf021","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T11:32:40Z","timestamp":1755603160000},"source":"Crossref","is-referenced-by-count":10,"title":["Molecular mechanisms and genetic features of cholangiocarcinoma: implications for targeted therapeutic strategies"],"prefix":"10.1093","volume":"8","author":[{"given":"Xiao","family":"Lu","sequence":"first","affiliation":[{"name":"Naval Medical University Department of Cell Biology, , Shanghai 200433 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoujia","family":"Xu","sequence":"additional","affiliation":[{"name":"Naval Medical University Department of Cell Biology, , Shanghai 200433 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Deng","sequence":"additional","affiliation":[{"name":"School of Medicine, Johns Hopkins University , Baltimore, MD 21218 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"Naval Medical University Department of Cell Biology, , Shanghai 200433 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Chen","sequence":"additional","affiliation":[{"name":"Naval Medical University Department of Cell Biology, , Shanghai 200433 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"2025091916234920600_bib1","doi-asserted-by":"publisher","first-page":"E3806","DOI":"10.1073\/pnas.1619416114","article-title":"Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands","volume":"114","author":"Nakagawa","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025091916234920600_bib2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/hep.31200","article-title":"Insights into the origin of intrahepatic cholangiocarcinoma from mouse models","volume":"72","author":"Zhu","year":"2020","journal-title":"Hepatol Baltim Md"},{"key":"2025091916234920600_bib3","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/liv.13998","article-title":"Classifications and misclassification in cholangiocarcinoma","volume":"39","author":"Cardinale","year":"2019","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"2025091916234920600_bib4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00595-024-02825-x","article-title":"Surgical interpretation of the WHO subclassification of intrahepatic cholangiocarcinoma: a narrative review","volume":"55","author":"Akita","year":"2025","journal-title":"Surg Today"},{"key":"2025091916234920600_bib5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.5858\/arpa.2022-0537-RA","article-title":"Cholangiocarcinoma: pathologic and molecular classification in the era of Precision medicine","volume":"148","author":"Gopal","year":"2024","journal-title":"Arch Pathol Lab Med"},{"key":"2025091916234920600_bib6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"2025091916234920600_bib7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma\u2014evolving concepts and therapeutic strategies","volume":"15","author":"Ilyas","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2025091916234920600_bib8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/liv.14093","article-title":"Anatomical, histomorphological and molecular classification of cholangiocarcinoma","volume":"39","author":"Kendall","year":"2019","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"2025091916234920600_bib9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/bs.apar.2018.10.001","article-title":"Update on pathogenesis of opisthorchiasis and cholangiocarcinoma","volume":"102","author":"Sripa","year":"2018","journal-title":"Adv Parasitol"},{"key":"2025091916234920600_bib10","doi-asserted-by":"publisher","first-page":"107064","DOI":"10.1016\/j.ejso.2023.107064","article-title":"Epidemiology of cholangiocarcinoma","volume":"51","author":"Qurashi","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"2025091916234920600_bib11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","article-title":"Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma","volume":"71","author":"Bertuccio","year":"2019","journal-title":"J Hepatol"},{"key":"2025091916234920600_bib12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2025091916234920600_bib13","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","article-title":"Current epidemiology of cholangiocarcinoma in Western countries","volume":"77","author":"Vithayathil","year":"2022","journal-title":"J Hepatol"},{"key":"2025091916234920600_bib14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025091916234920600_bib15","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1080\/0284186X.2019.1590634","article-title":"Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study","volume":"58","author":"Strijker","year":"2019","journal-title":"Acta Oncol Stockh Swed"},{"key":"2025091916234920600_bib16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat Rev Dis Primer"},{"key":"2025091916234920600_bib17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.5604\/01.3001.0012.0929","article-title":"Racial, ethnic, and age disparities in incidence and survival of intrahepatic cholangiocarcinoma in the United States; 1995-2014","volume":"17","author":"Antwi","year":"2018","journal-title":"Ann Hepatol"},{"key":"2025091916234920600_bib18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.21037\/jgo.2018.12.07","article-title":"Trends in surgery and disparities in receipt of surgery for intrahepatic cholangiocarcinoma in the US: 2005-2014","volume":"10","author":"Ransome","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"2025091916234920600_bib19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jhep.2019.09.007","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis","volume":"72","author":"Clements","year":"2020","journal-title":"J Hepatol"},{"key":"2025091916234920600_bib20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1136\/oemed-2017-104603","article-title":"Occupational exposure to asbestos and risk of cholangiocarcinoma: a population-based case-control study in four Nordic countries","volume":"75","author":"Farioli","year":"2018","journal-title":"Occup Environ Med"},{"key":"2025091916234920600_bib24","doi-asserted-by":"publisher","first-page":"e0186643","DOI":"10.1371\/journal.pone.0186643","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based study in SEER-Medicare","volume":"12","author":"Petrick","year":"2017","journal-title":"PLoS One"},{"key":"2025091916234920600_bib25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/CEJ.0b013e3283481d89","article-title":"Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis","volume":"21","author":"Jing","year":"2012","journal-title":"Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP"},{"key":"2025091916234920600_bib26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12876-017-0696-4","article-title":"Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis","volume":"17","author":"Wongjarupong","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"2025091916234920600_bib27","article-title":"Associations between metabolic syndrome and cholangiocarcinoma risk: A large-scale population-based cohort study","author":"Chen","journal-title":"Hepatology"},{"key":"2025091916234920600_bib28","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1349-7006.2009.01458.x","article-title":"Epidemiology of cholangiocarcinoma: an update focusing on risk factors","volume":"101","author":"Shin","year":"2010","journal-title":"Cancer Sci"},{"key":"2025091916234920600_bib29","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1136\/oemed-2015-103427","article-title":"Relationship between cumulative exposure to 1,2-dichloropropane and incidence risk of cholangiocarcinoma among offset printing workers","volume":"73","author":"Kumagai","year":"2016","journal-title":"Occup Environ Med"},{"key":"2025091916234920600_bib30","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s10552-013-0167-3","article-title":"Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case-control analysis","volume":"24","author":"Brandi","year":"2013","journal-title":"Cancer Causes Control CCC"},{"key":"2025091916234920600_bib21","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.2147\/CMAR.S173197","article-title":"Aspirin use is associated with a reduced risk of cholangiocarcinoma: a systematic review and meta-analysis","volume":"10","author":"Xiong","year":"2018","journal-title":"Cancer Manag Res"},{"key":"2025091916234920600_bib22","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1136\/gutjnl-2018-317504","article-title":"Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink","volume":"68","author":"Liu","year":"2019","journal-title":"Gut"},{"key":"2025091916234920600_bib23","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1001\/jamaoncol.2019.4328","article-title":"Association between aspirin use and biliary tract cancer survival","volume":"5","author":"Jackson","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025091916234920600_bib31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025091916234920600_bib32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ccell.2017.05.009","article-title":"Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma","volume":"32","author":"Chaisaingmongkol","year":"2017","journal-title":"Cancer Cell"},{"key":"2025091916234920600_bib33","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.bbadis.2017.06.014","article-title":"Epigenome dysregulation in cholangiocarcinoma","volume":"1864","author":"O'Rourke","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2025091916234920600_bib34","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1053\/j.gastro.2013.01.001","article-title":"Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes","volume":"144","author":"Sia","year":"2013","journal-title":"Gastroenterology"},{"key":"2025091916234920600_bib35","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/ng.2813","article-title":"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas","volume":"45","author":"Jiao","year":"2013","journal-title":"Nat Genet"},{"key":"2025091916234920600_bib36","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nature11287","article-title":"A restricted cell population propagates glioblastoma growth after chemotherapy","volume":"488","author":"Chen","year":"2012","journal-title":"Nature"},{"key":"2025091916234920600_bib37","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature13441","article-title":"Mutant IDH inhibits HNF-4\u03b1 to block hepatocyte differentiation and promote biliary cancer","volume":"513","author":"Saha","year":"2014","journal-title":"Nature"},{"key":"2025091916234920600_bib38","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1016\/j.celrep.2017.06.008","article-title":"Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles","volume":"19","author":"Farshidfar","year":"2017","journal-title":"Cell Rep"},{"key":"2025091916234920600_bib39","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-1383","article-title":"Generation of a biliary tract cancer cell line atlas identifies molecular subtypes and therapeutic targets","author":"Vijay","year":"2025","journal-title":"Cancer Discov"},{"key":"2025091916234920600_bib40","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1038\/ncomms6696","article-title":"Mutational landscape of intrahepatic cholangiocarcinoma","volume":"5","author":"Zou","year":"2014","journal-title":"Nat Commun"},{"key":"2025091916234920600_bib41","doi-asserted-by":"publisher","first-page":"102170","DOI":"10.1016\/j.ctrv.2021.102170","article-title":"Targeting FGFR inhibition in cholangiocarcinoma","volume":"95","author":"Goyal","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"2025091916234920600_bib42","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.18632\/oncotarget.1943","article-title":"Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups","volume":"5","author":"Simbolo","year":"2014","journal-title":"Oncotarget"},{"key":"2025091916234920600_bib43","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2025091916234920600_bib44","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1038\/s41467-022-30708-7","article-title":"The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"key":"2025091916234920600_bib45","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"key":"2025091916234920600_bib46","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.trecan.2019.05.002","article-title":"Epigenome remodeling in cholangiocarcinoma","volume":"5","author":"O'Rourke","year":"2019","journal-title":"Trends Cancer"},{"key":"2025091916234920600_bib47","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00535-024-02175-y","article-title":"FGFR2 fusions assessed by NGS, FISH, and immunohistochemistry in intrahepatic cholangiocarcinoma","volume":"60","author":"Cao","year":"2025","journal-title":"J Gastroenterol"},{"key":"2025091916234920600_bib48","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/hep.26721","article-title":"Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway","volume":"59","author":"Goeppert","year":"2014","journal-title":"Hepatol Baltim Md"},{"key":"2025091916234920600_bib49","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jhep.2017.02.017","article-title":"SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma","volume":"67","author":"Merino-Azpitarte","year":"2017","journal-title":"J Hepatol"},{"key":"2025091916234920600_bib50","doi-asserted-by":"publisher","first-page":"dmm050358","DOI":"10.1242\/dmm.050358","article-title":"Smad4 restricts injury-provoked biliary proliferation and carcinogenesis","volume":"17","author":"Alexander","year":"2024","journal-title":"Dis Model Mech"},{"key":"2025091916234920600_bib51","doi-asserted-by":"publisher","first-page":"7337","DOI":"10.3390\/ijms25137337","article-title":"Molecular targeting of the isocitrate dehydrogenase pathway and the implications for cancer therapy","volume":"25","author":"Ivanov","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025091916234920600_bib52","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/embor.2011.43","article-title":"The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases","volume":"12","author":"Chowdhury","year":"2011","journal-title":"EMBO Rep"},{"key":"2025091916234920600_bib53","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1038\/onc.2012.315","article-title":"Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"key":"2025091916234920600_bib54","doi-asserted-by":"publisher","first-page":"780","DOI":"10.3390\/cells9030780","article-title":"Role of histone deacetylases in carcinogenesis: potential Role in cholangiocarcinoma","volume":"9","author":"Pant","year":"2020","journal-title":"Cells"},{"key":"2025091916234920600_bib55","doi-asserted-by":"publisher","first-page":"99402","DOI":"10.18632\/oncotarget.19660","article-title":"Down-regulation of HDAC3 inhibits growth of cholangiocarcinoma by inducing apoptosis","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"2025091916234920600_bib56","doi-asserted-by":"publisher","first-page":"75441","DOI":"10.18632\/oncotarget.12254","article-title":"TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors","volume":"7","author":"He","year":"2016","journal-title":"Oncotarget"},{"key":"2025091916234920600_bib57","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.hbpd.2019.07.006","article-title":"Decreased expression of HDAC8 indicates poor prognosis in patients with intrahepatic cholangiocarcinoma","volume":"18","author":"Zhu","year":"2019","journal-title":"Hepatobiliary Pancreat Dis Int HBPD INT"},{"key":"2025091916234920600_bib58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12964-019-0332-8","article-title":"Low levels of pyruvate induced by a positive feedback loop protects cholangiocarcinoma cells from apoptosis","volume":"17","author":"Zhang","year":"2019","journal-title":"Cell Commun Signal CCS"},{"key":"2025091916234920600_bib59","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.neo.2019.03.002","article-title":"The SIRT2\/cMYC pathway inhibits peroxidation-related apoptosis In cholangiocarcinoma through metabolic reprogramming","volume":"21","author":"Xu","year":"2019","journal-title":"Neoplasia N Y N"},{"key":"2025091916234920600_bib60","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1055\/s-0038-1676097","article-title":"Noncoding RNA in cholangiocarcinoma","volume":"39","author":"Salati","year":"2018","journal-title":"Semin Liver Dis"},{"key":"2025091916234920600_bib61","doi-asserted-by":"publisher","first-page":"100","DOI":"10.7150\/jca.21785","article-title":"NcRNAs and cholangiocarcinoma","volume":"9","author":"Zheng","year":"2018","journal-title":"J Cancer"},{"key":"2025091916234920600_bib62","doi-asserted-by":"publisher","first-page":"6002","DOI":"10.3390\/ijms25116002","article-title":"The diagnostic and prognostic potentials of non-coding RNA in cholangiocarcinoma","volume":"25","author":"Andrade","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025091916234920600_bib63","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s44319-024-00075-z","article-title":"TGF\u03b2-induced long non-coding RNA LINC00313 activates wnt signaling and promotes cholangiocarcinoma","volume":"25","author":"Papoutsoglou","year":"2024","journal-title":"EMBO Rep"},{"key":"2025091916234920600_bib64","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41417-024-00726-2","article-title":"LOXL1-AS1 inhibits JAK2 ubiquitination and promotes cholangiocarcinoma progression through JAK2\/STAT3 signaling","volume":"31","author":"Yu","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"2025091916234920600_bib65","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.7150\/ijbs.66224","article-title":"YY1-induced DLEU1\/miR-149-5p promotes malignant biological behavior of cholangiocarcinoma through upregulating YAP1\/TEAD2\/SOX2","volume":"18","author":"Li","year":"2022","journal-title":"Int J Biol Sci"},{"key":"2025091916234920600_bib66","doi-asserted-by":"publisher","first-page":"217596","DOI":"10.1016\/j.canlet.2025.217596","article-title":"Tumor-derived exosomal LINC01812 induces M2 macrophage polarization to promote perineural invasion in cholangiocarcinoma","volume":"617","author":"Wang","year":"2025","journal-title":"Cancer Lett"},{"key":"2025091916234920600_bib67","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12943-024-01950-y","article-title":"CircPCNXL2 promotes tumor growth and metastasis by interacting with STRAP to regulate ERK signaling in intrahepatic cholangiocarcinoma","volume":"23","author":"Liu","year":"2024","journal-title":"Mol Cancer"},{"key":"2025091916234920600_bib68","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41419-022-04534-0","article-title":"Tumor-associated macrophages promote cholangiocarcinoma progression via exosomal Circ_0020256","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis"},{"key":"2025091916234920600_bib69","doi-asserted-by":"publisher","first-page":"111965","DOI":"10.1016\/j.cellsig.2025.111965","article-title":"Circ_0084927 promotes progression of intrahepatic cholangiocarcinoma by sponging miR-4725-5p to activate the PDPK1\/AKT\/mTOR signaling pathway","volume":"134","author":"Xie","year":"2025","journal-title":"Cell Signal"},{"key":"2025091916234920600_bib70","doi-asserted-by":"publisher","first-page":"115290","DOI":"10.1016\/j.biopha.2023.115290","article-title":"The roles of epigenetic regulation in cholangiocarcinogenesis","volume":"166","author":"Zhong","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"2025091916234920600_bib71","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3390\/genes13081479","article-title":"Emerging role of microRNA dysregulation in diagnosis and prognosis of extrahepatic cholangiocarcinoma","volume":"13","author":"Prinz","year":"2022","journal-title":"Genes"},{"key":"2025091916234920600_bib72","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1053\/j.gastro.2006.02.057","article-title":"Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines","volume":"130","author":"Meng","year":"2006","journal-title":"Gastroenterology"},{"key":"2025091916234920600_bib73","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1053\/j.gastro.2012.03.045","article-title":"MicroRNA-26a promotes cholangiocarcinoma growth by activating \u03b2-catenin","volume":"143","author":"Zhang","year":"2012","journal-title":"Gastroenterology"},{"key":"2025091916234920600_bib74","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/hep.29116","article-title":"MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma","volume":"66","author":"Li","year":"2017","journal-title":"Hepatol Baltim Md"},{"key":"2025091916234920600_bib75","doi-asserted-by":"publisher","first-page":"9720","DOI":"10.1002\/jcb.27286","article-title":"miR-383 promotes cholangiocarcinoma cell proliferation, migration, and invasion through targeting IRF1","volume":"119","author":"Wan","year":"2018","journal-title":"J Cell Biochem"},{"key":"2025091916234920600_bib76","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1002\/hep.25890","article-title":"Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma","volume":"56","author":"Oishi","year":"2012","journal-title":"Hepatol Baltim Md"},{"key":"2025091916234920600_bib77","first-page":"4684","article-title":"MicroRNA-21 regulates biological behavior by inducing EMT in human cholangiocarcinoma","volume":"8","author":"Liu","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"2025091916234920600_bib78","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jhep.2021.08.027","article-title":"Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription","volume":"76","author":"Chen","year":"2022","journal-title":"J Hepatol"},{"key":"2025091916234920600_bib79","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1053\/j.gastro.2011.12.005","article-title":"Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors","volume":"142","author":"Andersen","year":"2012","journal-title":"Gastroenterology"},{"key":"2025091916234920600_bib80","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1053\/j.gastro.2013.02.018","article-title":"Genomic decoding of intrahepatic cholangiocarcinoma reveals therapeutic opportunities","volume":"144","author":"Andersen","year":"2013","journal-title":"Gastroenterology"},{"key":"2025091916234920600_bib81","doi-asserted-by":"publisher","first-page":"7033","DOI":"10.3748\/wjg.14.7033","article-title":"Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma","volume":"14","author":"Sirica","year":"2008","journal-title":"World J Gastroenterol"},{"key":"2025091916234920600_bib82","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/1541-7786.MCR-13-0503","article-title":"Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development","volume":"12","author":"Lozano","year":"2014","journal-title":"Mol Cancer Res MCR"},{"key":"2025091916234920600_bib83","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.bbadis.2017.08.016","article-title":"Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression","volume":"1864","author":"Erice","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2025091916234920600_bib84","doi-asserted-by":"publisher","first-page":"455","DOI":"10.4254\/wjh.v9.i9.455","article-title":"Tumor reactive stroma in cholangiocarcinoma: the fuel behind cancer aggressiveness","volume":"9","author":"Brivio","year":"2017","journal-title":"World J Hepatol"},{"key":"2025091916234920600_bib85","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1158\/1078-0432.CCR-14-3296","article-title":"Molecular pathogenesis and targeted therapies for intrahepatic cholangiocarcinoma","volume":"22","author":"Moeini","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2025091916234920600_bib86","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatol Baltim Md"},{"key":"2025091916234920600_bib87","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","article-title":"Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma","volume":"45","author":"Graham","year":"2014","journal-title":"Hum Pathol"},{"key":"2025091916234920600_bib88","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"2025091916234920600_bib89","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.1007\/s13277-015-3261-1","article-title":"Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis","volume":"36","author":"Xue","year":"2015","journal-title":"Tumour Biol J Int Soc Oncodevelopmental Biol Med"},{"key":"2025091916234920600_bib90","doi-asserted-by":"publisher","first-page":"e22087","DOI":"10.1016\/j.heliyon.2023.e22087","article-title":"LncRNA-HANR exacerbates malignant behaviors of cholangiocarcinoma cells through activating Notch pathway","volume":"9","author":"Zhou","year":"2023","journal-title":"Heliyon"},{"key":"2025091916234920600_bib91","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1158\/1538-7445.AM2025-193","article-title":"Abstract 193: Notch pathway activation predicts poor prognosis in combined hepatocellular carcinoma-cholangiocarcinoma","volume":"85","author":"Kim","year":"2025","journal-title":"Cancer Res"},{"key":"2025091916234920600_bib92","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/ejhg.2011.181","article-title":"Alagille syndrome: pathogenesis, diagnosis and management","volume":"20","author":"Turnpenny","year":"2012","journal-title":"Eur J Hum Genet EJHG"},{"key":"2025091916234920600_bib93","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/hep.27268","article-title":"Emerging roles of notch signaling in liver disease","volume":"61","author":"Geisler","year":"2015","journal-title":"Hepatol Baltim Md"},{"key":"2025091916234920600_bib94","first-page":"3272","article-title":"Clinicopathological significance of aberrant Notch receptors in intrahepatic cholangiocarcinoma","volume":"7","author":"Wu","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"2025091916234920600_bib95","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.3892\/or.2014.3123","article-title":"Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro","volume":"31","author":"Wu","year":"2014","journal-title":"Oncol Rep"},{"key":"2025091916234920600_bib96","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1186\/s12885-016-2919-4","article-title":"Aberrant activation of Notch signaling in extrahepatic cholangiocarcinoma: clinicopathological features and therapeutic potential for cancer stem cell-like properties","volume":"16","author":"Aoki","year":"2016","journal-title":"BMC Cancer"},{"key":"2025091916234920600_bib97","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ccr.2013.04.019","article-title":"A critical role for notch signaling in the formation of cholangiocellular carcinomas","volume":"23","author":"Zender","year":"2013","journal-title":"Cancer Cell"},{"key":"2025091916234920600_bib98","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1038\/s41388-018-0188-1","article-title":"Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice","volume":"37","author":"Wang","year":"2018","journal-title":"Oncogene"},{"key":"2025091916234920600_bib99","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1172\/JCI63212","article-title":"Cholangiocarcinomas can originate from hepatocytes in mice","volume":"122","author":"Fan","year":"2012","journal-title":"J Clin Invest"},{"key":"2025091916234920600_bib100","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1172\/JCI63065","article-title":"Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes","volume":"122","author":"Sekiya","year":"2012","journal-title":"J Clin Invest"},{"key":"2025091916234920600_bib101","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/hep.27566","article-title":"Differential effects of targeting Notch receptors in a mouse model of liver cancer","volume":"61","author":"Huntzicker","year":"2015","journal-title":"Hepatol Baltim Md"},{"key":"2025091916234920600_bib102","doi-asserted-by":"publisher","first-page":"12250","DOI":"10.1073\/pnas.1600067113","article-title":"Notch3 drives development and progression of cholangiocarcinoma","volume":"113","author":"Guest","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025091916234920600_bib103","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.3390\/cells12081141","article-title":"Impact of aberrant \u03b2-catenin pathway on cholangiocarcinoma heterogeneity","volume":"12","author":"Lozano","year":"2023","journal-title":"Cells"},{"key":"2025091916234920600_bib104","doi-asserted-by":"publisher","first-page":"101404","DOI":"10.1016\/j.jcmgh.2024.101404","article-title":"RBM39 Enhances cholangiocarcinoma growth through EZH2-mediated WNT7B\/\u03b2-catenin pathway","volume":"19","author":"Liu","year":"2025","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2025091916234920600_bib105","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1172\/JCI76452","article-title":"WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited","volume":"125","author":"Boulter","year":"2015","journal-title":"J Clin Invest"},{"key":"2025091916234920600_bib106","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1007\/s13277-014-1698-2","article-title":"Activated macrophages promote wnt\/\u03b2-catenin signaling in cholangiocarcinoma cells","volume":"35","author":"Loilome","year":"2014","journal-title":"Tumour Biol J Int Soc Oncodevelopmental Biol Med"},{"key":"2025091916234920600_bib107","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41575-018-0075-9","article-title":"Wnt-\u03b2-catenin signalling in liver development, health and disease","volume":"16","author":"Perugorria","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025091916234920600_bib108","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10137","article-title":"Role of YAP\/TAZ in mechanotransduction","volume":"474","author":"Dupont","year":"2011","journal-title":"Nature"},{"key":"2025091916234920600_bib109","doi-asserted-by":"publisher","first-page":"17206","DOI":"10.18632\/oncotarget.4043","article-title":"YAP is a critical oncogene in human cholangiocarcinoma","volume":"6","author":"Pei","year":"2015","journal-title":"Oncotarget"},{"key":"2025091916234920600_bib110","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1053\/j.gastro.2014.05.004","article-title":"Activation of \u03b2-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice","volume":"147","author":"Tao","year":"2014","journal-title":"Gastroenterology"},{"key":"2025091916234920600_bib111","doi-asserted-by":"publisher","first-page":"8031","DOI":"10.1074\/jbc.M115.698472","article-title":"A hippo and fibroblast growth factor receptor autocrine pathway in Cholangiocarcinoma","volume":"291","author":"Ilyas","year":"2016","journal-title":"J Biol Chem"},{"key":"2025091916234920600_bib112","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/jcb.26246","article-title":"Platelet-derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation","volume":"119","author":"Smoot","year":"2018","journal-title":"J Cell Biochem"},{"key":"2025091916234920600_bib113","doi-asserted-by":"publisher","first-page":"101773","DOI":"10.1016\/j.aohep.2024.101773","article-title":"Tumor-associated macrophages contribute to cholangiocarcinoma progression and chemoresistance through activation of ID1","volume":"30","author":"Guo","year":"2025","journal-title":"Ann Hepatol"},{"key":"2025091916234920600_bib114","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1158\/0008-5472.CAN-24-0147","article-title":"CLK1 Activates YAP to promote intrahepatic cholangiocarcinogenesis","volume":"85","author":"Xue","year":"2025","journal-title":"Cancer Res"},{"key":"2025091916234920600_bib115","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41418-024-01407-1","article-title":"The AKR1C1\u2013CYP1B1\u2013cAMP signaling axis controls tumorigenicity and ferroptosis susceptibility of extrahepatic cholangiocarcinoma","volume":"32","author":"Liu","year":"2025","journal-title":"Cell Death Differ"},{"key":"2025091916234920600_bib116","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s12672-025-02199-7","article-title":"MUC3A promotes the progression of cholangiocarcinoma through the MAPK\/ERK pathway","volume":"16","author":"Feng","year":"2025","journal-title":"Discov Oncol"},{"key":"2025091916234920600_bib117","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41418-024-01361-y","article-title":"AMDHD1 acts as a tumor suppressor and contributes to activation of TGF-\u03b2 signaling pathway in cholangiocarcinoma","volume":"32","author":"Ma","year":"2025","journal-title":"Cell Death Differ"},{"key":"2025091916234920600_bib118","doi-asserted-by":"publisher","first-page":"e29683","DOI":"10.1016\/j.heliyon.2024.e29683","article-title":"Lipopolysaccharide promotes cancer cell migration and invasion through METTL3\/PI3K\/AKT signaling in human cholangiocarcinoma","volume":"10","author":"Ke","year":"2024","journal-title":"Heliyon"},{"key":"2025091916234920600_bib119","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41419-024-06775-7","article-title":"MAL2 reprograms lipid metabolism in intrahepatic cholangiocarcinoma via EGFR\/SREBP-1 pathway based on single-cell RNA sequencing","volume":"15","author":"Huang","year":"2024","journal-title":"Cell Death Dis"},{"key":"2025091916234920600_bib120","doi-asserted-by":"publisher","first-page":"e2308711","DOI":"10.1002\/advs.202308711","article-title":"VEGF-FGF signaling activates quiescent CD63+ liver stem cells to proliferate and differentiate","volume":"11","author":"Chen","year":"2024","journal-title":"Adv Sci Weinh Baden-Wurtt Ger"},{"key":"2025091916234920600_bib121","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4080","article-title":"Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma","author":"Silverman","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025091916234920600_bib122","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4087","article-title":"Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH)","author":"Javle","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025091916234920600_bib123","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"2025091916234920600_bib124","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov"},{"key":"2025091916234920600_bib125","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025091916234920600_bib126","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025091916234920600_bib127","doi-asserted-by":"publisher","first-page":"103488","DOI":"10.1016\/j.esmoop.2024.103488","article-title":"An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202\u2606","volume":"9","author":"Vogel","year":"2024","journal-title":"ESMO Open"},{"key":"2025091916234920600_bib128","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"key":"2025091916234920600_bib130","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"2025091916234920600_bib131","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.1158\/1078-0432.CCR-18-3334","article-title":"Multicenter Phase I study of Erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors","volume":"25","author":"Bahleda","year":"2019","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2025091916234920600_bib132","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025091916234920600_bib133","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1186\/s12885-024-12584-0","article-title":"Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial","volume":"24","author":"Park","year":"2024","journal-title":"BMC Cancer"},{"key":"2025091916234920600_bib134","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1038\/s41467-024-47514-y","article-title":"FGFR inhibition blocks NF-kB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma","volume":"15","author":"Zhen","year":"2024","journal-title":"Nat Commun"},{"key":"2025091916234920600_bib135","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2019","journal-title":"Br J Cancer"},{"key":"2025091916234920600_bib136","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1200\/JCO.2024.42.3_suppl.434","article-title":"Efficacy and safety results of FGFR1-3 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma: results from phase II clinical trial","volume":"42","author":"Javle","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025091916234920600_bib137","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1200\/JCO.2021.39.15_suppl.4092","article-title":"Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations","volume":"39","author":"Guo","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025091916234920600_bib138","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1200\/JCO.2022.40.4_suppl.427","article-title":"Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: interim results from the phase 2 study FIDES-01","volume":"40","author":"Javle","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025091916234920600_bib139","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/curroncol32010044","article-title":"IDH mutant cholangiocarcinoma: pathogenesis, management, and future therapies","volume":"32","author":"Bray","year":"2025","journal-title":"Curr Oncol"},{"key":"2025091916234920600_bib140","doi-asserted-by":"publisher","first-page":"751","DOI":"10.21037\/jgo.2019.03.10","article-title":"Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review","volume":"10","author":"Boscoe","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"2025091916234920600_bib141","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025091916234920600_bib142","article-title":"FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma","author":"FDA"},{"key":"2025091916234920600_bib143","doi-asserted-by":"publisher","first-page":"eaal2463","DOI":"10.1126\/scitranslmed.aal2463","article-title":"2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","volume":"9","author":"Sulkowski","year":"2017","journal-title":"Sci Transl Med"},{"key":"2025091916234920600_bib144","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ccell.2016.05.018","article-title":"Mutant IDH1 downregulates ATM and alters DNA repair and sensitivity to DNA damage independent of TET2","volume":"30","author":"Inoue","year":"2016","journal-title":"Cancer Cell"},{"key":"2025091916234920600_bib145","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"2025091916234920600_bib146","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025091916234920600_bib147","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.4006","article-title":"Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): an investigator-initiated multicenter phase 2 study (HERB trial)","author":"Ohba","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025091916234920600_bib148","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19\u201314)","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025091916234920600_bib149","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ygyno.2023.12.004","article-title":"Targeting HER2-mutant metastatic cervical cancer with neratinib: final results from the phase 2 SUMMIT basket trial","volume":"181","author":"Friedman","year":"2024","journal-title":"Gynecol Oncol"},{"key":"2025091916234920600_bib150","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.299","article-title":"Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): results from a phase I study","author":"Meric-Bernstam","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025091916234920600_bib151","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"2025091916234920600_bib152","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New Horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"key":"2025091916234920600_bib153","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025091916234920600_bib154","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"key":"2025091916234920600_bib155","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in Human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"2025091916234920600_bib156","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRASG12C mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2025091916234920600_bib157","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.604","article-title":"Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors","author":"Shen","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025091916234920600_bib158","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41591-023-02696-8","article-title":"Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial","volume":"30","author":"Desai","year":"2024","journal-title":"Nat Med"},{"key":"2025091916234920600_bib159","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J Med Chem"},{"key":"2025091916234920600_bib160","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","article-title":"Pan-KRAS inhibitor disables oncogenic signalling and tumour growth","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"2025091916234920600_bib161","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"key":"2025091916234920600_bib162","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41698-021-00206-y","article-title":"Genomic context of NTRK1\/2\/3 fusion-positive tumours from a large real-world population","volume":"5","author":"Westphalen","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"2025091916234920600_bib163","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025091916234920600_bib164","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025091916234920600_bib165","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41698-023-00347-2","article-title":"Genomic landscape of 891 RET fusions detected across diverse solid tumor types","volume":"7","author":"Parimi","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"2025091916234920600_bib166","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat Med"},{"key":"2025091916234920600_bib167","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025091916234920600_bib168","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1158\/1078-0432.CCR-23-0459","article-title":"FDA approval summary: Selpercatinib for the treatment of advanced RET fusion-positive solid tumors","volume":"29","author":"Duke","year":"2023","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2025091916234920600_bib169","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ajpath.2024.10.013","article-title":"Genetic, epigenetic, and microenvironmental drivers of cholangiocarcinoma","volume":"195","author":"Putatunda","year":"2025","journal-title":"Am J Pathol"},{"key":"2025091916234920600_bib170","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2025091916234920600_bib171","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3390\/cancers17030555","article-title":"Biomarkers for the evaluation of immunotherapy in patients with cholangiocarcinoma","volume":"17","author":"Bousou","year":"2025","journal-title":"Cancers"},{"key":"2025091916234920600_bib172","doi-asserted-by":"publisher","DOI":"10.1039\/D4MD00881B","article-title":"Recent progress in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma","author":"Kim","year":"2025"},{"key":"2025091916234920600_bib173","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/curroncol32020082","article-title":"Advancements in locoregional therapies for unresectable intrahepatic cholangiocarcinoma","volume":"32","author":"O'Donnell","year":"2025","journal-title":"Curr Oncol"},{"key":"2025091916234920600_bib174","doi-asserted-by":"publisher","first-page":"10886","DOI":"10.1038\/s41598-025-95142-3","article-title":"Whole exome sequencing of multi-regions reveals tumor heterogeneity in Opisthorchis viverrini-associated cholangiocarcinoma","volume":"15","author":"Sitthirak","year":"2025","journal-title":"Sci Rep"},{"key":"2025091916234920600_bib175","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41419-023-06406-7","article-title":"The heterogeneity of signaling pathways and drug responses in intrahepatic cholangiocarcinoma with distinct genetic mutations","volume":"15","author":"Feng","year":"2024","journal-title":"Cell Death Dis"},{"key":"2025091916234920600_bib176","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1158\/1078-0432.CCR-24-0657","article-title":"A novel approach to quantify heterogeneity of intrahepatic cholangiocarcinoma: the hidden-genome classifier","volume":"30","author":"Song","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025091916234920600_bib177","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3390\/life12060829","article-title":"Precision medicine in cholangiocarcinoma: past, present, and future","volume":"12","author":"Cheng","year":"2022","journal-title":"Life Basel Switz"},{"key":"2025091916234920600_bib178","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.03.028","article-title":"Cisplatin-induced disruption of mitochondrial divisome leads to enhanced cisplatin resistance in cholangiocarcinoma","author":"Lv","year":"2025","journal-title":"J Hepatol"},{"key":"2025091916234920600_bib179","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.dld.2023.08.052","article-title":"Intrahepatic cholangiocarcinoma: evolving strategies in management and treatment","volume":"56","author":"Bragazzi","year":"2024","journal-title":"Dig Liver Dis"},{"key":"2025091916234920600_bib180","doi-asserted-by":"publisher","first-page":"101951","DOI":"10.1016\/j.mcp.2024.101951","article-title":"Intrahepatic cholangiocarcinoma biomarkers: towards early detection and personalized pharmacological treatments","volume":"73","author":"Capuozzo","year":"2024","journal-title":"Mol Cell Probes"},{"key":"2025091916234920600_bib181","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1111\/cas.16143","article-title":"Serum ITIH5 as a novel diagnostic biomarker in cholangiocarcinoma","volume":"115","author":"Chen","year":"2024","journal-title":"Cancer Sci"},{"key":"2025091916234920600_bib182","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/s41467-024-44748-8","article-title":"A transcriptome based molecular classification scheme for cholangiocarcinoma and subtype-derived prognostic biomarker","volume":"15","author":"Fan","year":"2024","journal-title":"Nat Commun"},{"key":"2025091916234920600_bib183","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2025.04.009","article-title":"Large-scale manufacturing of human gallbladder epithelial cell products and derived hepatocytes via a chemically defined approach","author":"Chen","year":"2025","journal-title":"Trends Biotechnol"}],"container-title":["Precision Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pcm\/advance-article-pdf\/doi\/10.1093\/pcmedi\/pbaf021\/64095139\/pbaf021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pcm\/article-pdf\/8\/3\/pbaf021\/64095139\/pbaf021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pcm\/article-pdf\/8\/3\/pbaf021\/64095139\/pbaf021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T20:23:52Z","timestamp":1758313432000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pcm\/article\/doi\/10.1093\/pcmedi\/pbaf021\/8238633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,28]]},"references-count":182,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6,28]]}},"URL":"https:\/\/doi.org\/10.1093\/pcmedi\/pbaf021","relation":{},"ISSN":["2096-5303","2516-1571"],"issn-type":[{"value":"2096-5303","type":"print"},{"value":"2516-1571","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,6,28]]},"article-number":"pbaf021"}}